MetaCap

Collegium Pharmaceutical (COLL) vs Ironwood Pharmaceuticals (IRWD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ironwood Pharmaceuticals (IRWD) has outperformed Collegium Pharmaceutical (COLL) over the past year, gaining 48.7% versus a loss of 45.2%. Over five years, COLL leads with a +37.7% price change compared with -57.9% for IRWD. Ironwood Pharmaceuticals is the larger company by market cap ($778.1 million vs $768.2 million), about 1.0 times the size, while Collegium Pharmaceutical is growing revenue faster (+23.6% vs -15.7%).

On valuation, Ironwood Pharmaceuticals trades at a lower forward P/E (3.0x vs 3.5x for Collegium Pharmaceutical). Ironwood Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.1% versus 8.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COLL-45.24%IRWD+48.73%
+77%+9%-58%
Nov 21, 20251 yearNov 20, 2026
COLL+31.14%IRWD-59.83%
+177%+35%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COLL versus IRWD key metrics
MetricCOLLIRWD
Share price$24.72$4.70
Market cap$768.18M$778.09M
1-day change-1.94%-0.21%
YTD return-46.61%+39.47%
1-year return-45.24%+48.73%
5-year return+37.72%-57.89%
P/E ratio (TTM)22.685.22
Forward P/E3.493.00
EPS (TTM)$1.09$0.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$780.57M$296.15M
Revenue growth (YoY)+23.62%-15.72%
Net income (latest FY)$62.87M$24.02M
Gross margin59.35%—
Operating margin23.01%33.26%
Net margin8.05%8.11%
52-week high$50.79$5.78
52-week low$21.43$2.95
Distance from 52-week high-51.33%-18.69%
Analyst consensusstrong_buybuy
Avg. price target upside+77.99%+31.49%
Average volume754.45K2.15M
Shares outstanding31.08M165.55M
Employees423100
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IRWD has outperformed COLL by 94.0 percentage points over the past year.
  • Collegium Pharmaceutical trades at a higher earnings multiple (22.7x vs 5.2x trailing P/E).
  • Collegium Pharmaceutical grew revenue faster in its latest fiscal year (+23.62% vs -15.72%).

About Collegium Pharmaceutical

COLL stock →

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees

About Ironwood Pharmaceuticals

IRWD stock →

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

COLL vs IRWD FAQ

Which is bigger, Collegium Pharmaceutical or Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals (IRWD) is larger, with a market capitalization of $778.09M compared with $768.18M for Collegium Pharmaceutical (COLL).

Which stock has performed better over the past year, COLL or IRWD?

IRWD returned +48.73% over the past 12 months, compared with -45.24% for COLL (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, COLL or IRWD?

IRWD has the lower trailing P/E at 5.2, versus 22.7 for COLL. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Collegium Pharmaceutical and Ironwood Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons